<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667953</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 02602</org_study_id>
    <nct_id>NCT00667953</nct_id>
  </id_info>
  <brief_title>Study of Temzolomide and Gleevec in Advanced Melanoma</brief_title>
  <official_title>Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to evaluate the side effects of Gleevec when given in
      combination with Temzolomide; and to learn more about how these drugs work in the body and
      whether this combination is useful in treating patients with melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling subjects
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 9, 2011</completion_date>
  <primary_completion_date type="Actual">March 9, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and efficacy of combination therapy with Gleevec and Temzolomide in patients with advanced melanoma.</measure>
    <time_frame>Interim analysis after accrual of 17 patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the secondary endpoints of time to disease progression, duration of response, and overall survival of patients receiving Gleevec + Temozolomide</measure>
    <time_frame>Interim analysis after accruing 17 patients</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Melanoma</condition>
  <condition>Advanced Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec + Temozolomide</intervention_name>
    <description>Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle. Gleevec (600 mg) daily.</description>
    <arm_group_label>Arm A:</arm_group_label>
    <other_name>Imatinib mesylate</other_name>
    <other_name>temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed melanoma that is metastatic or unresectable and for which
             standard curative or palliative measures do not exist or are no longer effective

          -  Prior chemotherapy, immunotherapy, radiation therapy (Phase I portion only), cytokine,
             biologic, or vaccine therapy is permitted, however no prior treatment with
             temozolomide

          -  Measurable disease

          -  ECOG performance status &lt;= 2

          -  Life expectancy greater than 3 months

        Exclusion Criteria:

          -  No prior treatment with temozolomide or imatinib mesylate

          -  Organ allografts

          -  Prior radiotherapy, or prior intratumor injection therapy, to areas of measurable
             disease that are used as target indicator lesions, unless progression has occurred at
             that site or measurable disease has developed outside the treatment area

          -  Pregnancy or lactation

          -  History of second cancer

          -  Known hypersensitivity to temozolomide or imatinib

          -  Use of any experimental therapy within 3 weeks prior to baseline evaluations done
             prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Fecher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>tara mitchell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abramson CC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.9059</url>
    <description>Preliminary Results: Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma</description>
  </link>
  <results_reference>
    <citation>Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.</citation>
    <PMID>25252722</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <disposition_first_submitted>April 6, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 9, 2020</disposition_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temzolomide</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Advanced melanoma</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

